XTX Topco Ltd Takes $487,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• XTX Topco Ltd has acquired a new stake in Lantheus Holdings, Inc., purchasing 4,993 shares valued at approximately $487,000 in the first quarter.
• During the same quarter, several hedge funds significantly increased their holdings in Lantheus, with TD Asset Management Inc. raising its position by an astonishing 1,028.0%.
• Lantheus reported an EPS of $1.57 for the last quarter, missing the analyst consensus estimate, with a 4.1% decline in revenue year-over-year.

XTX Topco Ltd bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,993 shares of the medical equipment provider's stock, valued at approximately $487,000.

Other hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC grew its stake in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after purchasing an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC grew its stake in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after purchasing an additional 2,361,000 shares in the last quarter. TD Asset Management Inc grew its stake in Lantheus by 1,028.0% in the first quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider's stock worth $66,623,000 after purchasing an additional 622,100 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Lantheus in the fourth quarter worth approximately $36,183,000. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Up 4.3%

Shares of LNTH traded up $2.34 during midday trading on Friday, hitting $57.20. 2,503,494 shares of the company's stock traded hands, compared to its average volume of 1,884,666. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The firm's fifty day moving average is $76.31 and its 200-day moving average is $86.86. The company has a current ratio of 4.29, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of 15.21 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. During the same quarter in the prior year, the company posted $1.80 EPS. The business's revenue for the quarter was down 4.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LNTH. William Blair reissued a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. JMP Securities dropped their target price on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research report on Thursday. Mizuho dropped their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, B. Riley dropped their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $114.50.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.